RxDoctor Payments Data

Diana McNear, NP

Family · Mount Vernon, NYNPI 1699216697

Payments from drug & device makers

$2,308in general payments, 2019–2025

Across 29 payments — averaging $79.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$277
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$270
  • AbbVie$256
  • Takeda Pharmaceuticals U.S.A., Inc.$249
  • GSK$248
  • Biomerieux Inc$142
  • plus $866 from 11 others

What the payments were for

  • Food & beverage$2,308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,308 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$135,994
Medicare patients
106
Services billed
1,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban30$18,516
EliquisApixaban15$11,393
Diclofenac Sodium14$8,771
JanuviaSitagliptin Phosphate14$7,681
LinzessLinaclotide11$5,618
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,408
Mirtazapine54$1,777
Memantine Hcl20$1,544
Lidocaine12$973
Aripiprazole12$811
RivastigmineRivastigmine Tartrate13$710
Potassium Chloride38$636
Atorvastatin Calcium56$582
Levothyroxine Sodium40$488
Rosuvastatin Calcium44$478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$277$18,51630 claims
MerckJanuvia$24$7,68114 claims
AbbVieLinzess$256$5,61811 claims
GSKAnoro Ellipta$248$5,40812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Mount Vernon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →